A systematic review and meta-analysis of surgery delays and survival in breast, lung and colon cancers: Implication for surgical triage during the COVID-19 pandemic - 26/07/21
Abstract |
Background |
Thousands of cancer surgeries were delayed during the peak of the COVID-19 pandemic. This study examines if surgical delays impact survival for breast, lung and colon cancers.
Methods |
PubMed/MEDLINE, EMBASE, Cochrane Library and Web of Science were searched. Articles evaluating the relationship between delays in surgery and overall survival (OS), disease-free survival (DFS) or cancer-specific survival (CSS) were included.
Results |
Of the 14,422 articles screened, 25 were included in the review and 18 (totaling 2,533,355 patients) were pooled for meta-analyses. Delaying surgery for 12 weeks may decrease OS in breast (HR 1.46, 95%CI 1.28–1.65), lung (HR 1.04, 95%CI 1.02–1.06) and colon (HR 1.24, 95%CI 1.12–1.38) cancers. When breast cancers were analyzed by stage, OS was decreased in stages I (HR 1.27, 95%CI 1.16–1.40) and II (HR 1.13, 95%CI 1.02–1.24) but not in stage III (HR 1.20, 95%CI 0.94–1.53).
Conclusion |
Delaying breast, lung and colon cancer surgeries during the COVID-19 pandemic may decrease survival.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Delaying cancer surgeries during the COVID-19 pandemic may impact survival. |
• | Surgical delays of 12 weeks decreases survival in breast, lung and colon cancers. |
• | Surgical delays worsen survival in stage I and II breast cancers but not stage III. |
• | Triage recommendations for future waves of COVID-19 should consider this evidence. |
Keywords : COVID-19, Cancer, Breast, Lung, Colon, Surgery
Plan
Vol 222 - N° 2
P. 311-318 - août 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.